Affimed N.V. (0HL9.L)
0HL9.L Stock Price Chart
Explore Affimed N.V. interactive price chart. Choose custom timeframes to analyze 0HL9.L price movements and trends.
0HL9.L Company Profile
Discover essential business fundamentals and corporate details for Affimed N.V. (0HL9.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
13 Feb 2018
Employees
76.00
Website
https://www.affimed.comCEO
Shawn M. Leland Pharm.D.,
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
0HL9.L Financial Timeline
Browse a chronological timeline of Affimed N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Nov 2025
Upcoming earnings on 1 Sept 2025
Earnings released on 4 Jun 2025
EPS came in at -$0.38 surpassing the estimated -$0.52 by +27.59%.
Earnings released on 27 Mar 2025
EPS came in at -$0.70 surpassing the estimated -$0.84 by +15.91%.
Earnings released on 14 Nov 2024
EPS came in at -$1.05 falling short of the estimated -$1.03 by -1.82%, while revenue for the quarter reached $172.58K, missing expectations by -1.85%.
Earnings released on 5 Sept 2024
EPS came in at -$1.09 falling short of the estimated -$1.04 by -4.61%, while revenue for the quarter reached $225.80K, missing expectations by -80.52%.
Earnings released on 12 Jun 2024
EPS came in at -$1.36 surpassing the estimated -$1.67 by +18.42%, while revenue for the quarter reached $356.66K, missing expectations by -22.22%.
Earnings released on 28 Mar 2024
EPS came in at -$1.49 surpassing the estimated -$1.70 by +12.63%, while revenue for the quarter reached $5.42M, beating expectations by +227.49%.
Stock split effective on 11 Mar 2024
Shares were split 1:10, changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2023
EPS came in at -$1.72 surpassing the estimated -$1.95 by +11.67%, while revenue for the quarter reached $2.06M, beating expectations by +6.91%.
Earnings released on 30 Jun 2023
EPS came in at -$2.15 falling short of the estimated -$2.04 by -5.35%, while revenue for the quarter reached $2.30M, missing expectations by -50.60%.
Earnings released on 31 Mar 2023
EPS came in at -$2.33 falling short of the estimated -$2.08 by -12.12%, while revenue for the quarter reached $5.35M, missing expectations by -13.21%.
Earnings released on 31 Dec 2022
EPS came in at -$2.41 falling short of the estimated -$2.05 by -17.81%, while revenue for the quarter reached $12.75M, beating expectations by +84.22%.
Earnings released on 30 Sept 2022
EPS came in at -$1.08 surpassing the estimated -$1.69 by +36.38%, while revenue for the quarter reached $14.65M, beating expectations by +132.83%.
Earnings released on 30 Jun 2022
EPS came in at -$1.38 surpassing the estimated -$1.75 by +21.20%, while revenue for the quarter reached $7.89M, missing expectations by -10.64%.
Earnings released on 31 Mar 2022
EPS came in at -$1.49 surpassing the estimated -$1.95 by +23.41%, while revenue for the quarter reached $9.17M, missing expectations by -11.02%.
Dividend declared on 15 Mar 2022
A dividend of $0.03 per share was announced, adjusted to $0.29.
Earnings released on 31 Dec 2021
EPS came in at -$2.14 falling short of the estimated -$1.82 by -17.75%, while revenue for the quarter reached $12.26M, beating expectations by +36.50%.
Earnings released on 30 Sept 2021
EPS came in at -$1.66, while revenue for the quarter reached $10.32M.
Earnings released on 30 Jun 2021
EPS came in at -$1.86, while revenue for the quarter reached $11.91M.
Earnings released on 31 Mar 2021
EPS came in at $0.14, while revenue for the quarter reached $13.89M.
Earnings released on 31 Dec 2020
EPS came in at -$1.97, while revenue for the quarter reached $12.40M.
Earnings released on 30 Sept 2020
EPS came in at -$0.81, while revenue for the quarter reached $12.50M.
0HL9.L Stock Performance
Access detailed 0HL9.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.